Cargando…
Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro
NLC containing Gefitinib (NANOGEF) was prepared using stearic acid, sesame oil and surfactants (sodium lauryl sulfate and tween 80). NANOGEFs were evaluated for particle size, polydispersity index (PdI), zeta potential, entrapment efficiency (EE), stability, release studies and cytotoxicity studies...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241461/ https://www.ncbi.nlm.nih.gov/pubmed/32329374 http://dx.doi.org/10.1080/10717544.2020.1754526 |
_version_ | 1783537072723722240 |
---|---|
author | Makeen, Hafiz A. Mohan, Syam Al-Kasim, Mohamed Ahmed Attafi, Ibraheem M. Ahmed, Rayan A. Syed, Nabeel Kashan Sultan, Muhammad Hadi Al-Bratty, Mohammed Alhazmi, Hassan A. Safhi, Mohammed M. Ali, Raisuddin Intakhab Alam, M. |
author_facet | Makeen, Hafiz A. Mohan, Syam Al-Kasim, Mohamed Ahmed Attafi, Ibraheem M. Ahmed, Rayan A. Syed, Nabeel Kashan Sultan, Muhammad Hadi Al-Bratty, Mohammed Alhazmi, Hassan A. Safhi, Mohammed M. Ali, Raisuddin Intakhab Alam, M. |
author_sort | Makeen, Hafiz A. |
collection | PubMed |
description | NLC containing Gefitinib (NANOGEF) was prepared using stearic acid, sesame oil and surfactants (sodium lauryl sulfate and tween 80). NANOGEFs were evaluated for particle size, polydispersity index (PdI), zeta potential, entrapment efficiency (EE), stability, release studies and cytotoxicity studies (MTT assay). The optimized NANOGEF exhibited particle size of 74.06 ± 9.73 d.nm, PdI of 0.339 ± 0.029 and EE of 99.76 ± 0.015%. The TEM study revealed spherical shape of NANOGEF formulations. The slow and sustained release behavior was exhibited by all NANOGEFs. The effects of surfactants were observed not only on particle size but also on zeta potential, entrapment efficiency, stability and release studies. The MTT assay revealed 4.5 times increase in cytotoxicity for optimized NANOGEF (IC(50) = 4.642 µM) when compared with Gefitinib alone (IC(50) = 20.88 µM in HCT-116 cells). Thus NANOGEF may be considered as a potential drug delivery system for the cure of colon cancer. |
format | Online Article Text |
id | pubmed-7241461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-72414612020-06-01 Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro Makeen, Hafiz A. Mohan, Syam Al-Kasim, Mohamed Ahmed Attafi, Ibraheem M. Ahmed, Rayan A. Syed, Nabeel Kashan Sultan, Muhammad Hadi Al-Bratty, Mohammed Alhazmi, Hassan A. Safhi, Mohammed M. Ali, Raisuddin Intakhab Alam, M. Drug Deliv Research Article NLC containing Gefitinib (NANOGEF) was prepared using stearic acid, sesame oil and surfactants (sodium lauryl sulfate and tween 80). NANOGEFs were evaluated for particle size, polydispersity index (PdI), zeta potential, entrapment efficiency (EE), stability, release studies and cytotoxicity studies (MTT assay). The optimized NANOGEF exhibited particle size of 74.06 ± 9.73 d.nm, PdI of 0.339 ± 0.029 and EE of 99.76 ± 0.015%. The TEM study revealed spherical shape of NANOGEF formulations. The slow and sustained release behavior was exhibited by all NANOGEFs. The effects of surfactants were observed not only on particle size but also on zeta potential, entrapment efficiency, stability and release studies. The MTT assay revealed 4.5 times increase in cytotoxicity for optimized NANOGEF (IC(50) = 4.642 µM) when compared with Gefitinib alone (IC(50) = 20.88 µM in HCT-116 cells). Thus NANOGEF may be considered as a potential drug delivery system for the cure of colon cancer. Taylor & Francis 2020-04-24 /pmc/articles/PMC7241461/ /pubmed/32329374 http://dx.doi.org/10.1080/10717544.2020.1754526 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Makeen, Hafiz A. Mohan, Syam Al-Kasim, Mohamed Ahmed Attafi, Ibraheem M. Ahmed, Rayan A. Syed, Nabeel Kashan Sultan, Muhammad Hadi Al-Bratty, Mohammed Alhazmi, Hassan A. Safhi, Mohammed M. Ali, Raisuddin Intakhab Alam, M. Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro |
title | Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro |
title_full | Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro |
title_fullStr | Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro |
title_full_unstemmed | Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro |
title_short | Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro |
title_sort | gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241461/ https://www.ncbi.nlm.nih.gov/pubmed/32329374 http://dx.doi.org/10.1080/10717544.2020.1754526 |
work_keys_str_mv | AT makeenhafiza gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro AT mohansyam gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro AT alkasimmohamedahmed gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro AT attafiibraheemm gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro AT ahmedrayana gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro AT syednabeelkashan gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro AT sultanmuhammadhadi gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro AT albrattymohammed gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro AT alhazmihassana gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro AT safhimohammedm gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro AT aliraisuddin gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro AT intakhabalamm gefitinibloadednanostructuredlipidcarrierscharacterizationevaluationandantihumancoloncanceractivityinvitro |